US Stock MarketDetailed Quotes
ACXP Acurx Pharmaceuticals
- 2.430
- -0.050-2.02%
Close Jun 14 16:00 ET
- 2.350
- -0.080-3.29%
Post 18:55 ET
38.50MMarket Cap-2059P/E (TTM)
2.480High2.355Low46.33KVolume2.430Open2.480Pre Close110.99KTurnover0.35%Turnover RatioLossP/E (Static)15.84MShares8.82052wk High6.41P/B32.65MFloat Cap1.17052wk Low--Dividend TTM13.44MShs Float8.820Historical High--Div YieldTTM5.04%Amplitude1.170Historical Low2.395Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Acurx Pharmaceuticals Stock Forum
Acurx Pharmaceuticals Inc: Agreement With FDA Reached on Key Elements to Move Forward With Our International Phase 3 Clinical Trial Program
NEWS
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals announced the presentation of the Phase 2 clinical trial results of ibezapolstat for C. difficile Infection at ESCMID Global 2024 Scientific Conference. The results showed ibezapolstat's effectiveness in treating CDI and its potential as a therapeutic option against antimicrobial-resistant strains.
Dow Jones· 7 mins ago
2 MINUTES AGO, 7:00 AM EST
VIA PR NEWSWIRE
4 MINUTES AGO, 7:01 AM EST
VIA PR NEWSWIRE
No comment yet